NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Vancouver, Canada, May 18, 2023 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders (“AGM”) held on May 17, 2023. […]
NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291
Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in Q3 2023 Cash and investments of $18.0 million as of March 31, 2023 Vancouver, Canada. May 15, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the […]
NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
Phase 1b/2a trial expected to commence in Q3 2023 First readout anticipated in 2024 Vancouver, Canada. April 13, 2023 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, will be giving an oral presentation at the upcoming […]
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer
Vancouver, Canada. April 10, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Michael Kelly to the position of President & CEO effective April 10, 2023. Mr. Kelly […]
NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023
Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing Phase 1b/2a clinical trial of NVG-291 to include individuals with chronic and subacute spinal cord injuries Vancouver, Canada. March 30, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. February 23, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 285,000 incentive stock options to directors of the Company and 10,000 incentive stock options to […]
NervGen Pharma Announces Composition of Matter Patent for NVG-291 Granted by the US Patent and Trade Office
Vancouver, Canada. November 17, 2022 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the US Patent and Trade Office (USPTO) has issued US Patent No. 11,497,812 B2 Compositions and Methods for Inhibiting […]
NervGen Pharma Grants Stock Options
Vancouver, Canada. November 15, 2022 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company exercisable at a price of $1.74 […]
Five Off-road Mobility Devices to Get You Outside in Winter
By Codi Darnell November 15, 2022 It may feel like fall just arrived, but we are one month away from winter. Yes, winter is coming with its shorter days, frigid temperatures, and falling snow. Whether you love it or hate it, if you live in an area of the world that sees the cold and […]
NervGen Pharma Completes Dosing in its Third Multiple Ascending Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q3 2022 Results
Dosing completed in third dose cohort of multiple ascending dose (MAD) portion of Phase 1 clinical trial in postmenopausal females U.S. Food and Drug Administration (FDA) amendment of partial clinical hold allows for bridging cohorts of males and premenopausal females in the Phase 1 trial to commence Glenn Ives appointed as Lead Independent Director […]